Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Rhea-AI Summary
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy oncology company, has scheduled a conference call and webcast for Wednesday, May 14, 2025, at 4:30 p.m. ET. The event will provide a corporate update and discuss financial results for the first quarter of 2025.
Participants can join through North American toll-free number (888) 510-2154 or international line (437) 900-0527, using conference ID 28038. A webcast replay will be available on the company's Investor Relations page for three months, while a dial-in replay will be accessible for one week using (888) 660-6345 (North America) or (289) 819-1450 (International) with replay code 28038#.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ONCY declined 6.42%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET
Conference Call & Webcast
Date: Wednesday, May 14, 2025
Time: 4:30 p.m. ET
Dial In – North American Toll-Free: (888) 510-2154
Dial In – International: (437) 900-0527
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 28038
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights-302446465.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When is Oncolytics Biotech (ONCY) Q1 2025 earnings call?
How can I access Oncolytics Biotech's (ONCY) Q1 2025 earnings call?
How long will Oncolytics Biotech's (ONCY) Q1 2025 earnings call replay be available?
What is the replay information for Oncolytics Biotech's (ONCY) Q1 2025 earnings call?
